Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane-tazobactam study

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4387-4390

  Miller, Benjamin ^a   Popejoy, Myra W ^a   Hershberger, Ellie ^a   Steenbergen, Judith N ^a   Alverdy, John ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CEFUROXIME AXETIL; ERTAPENEM; GENTAMICIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ABDOMINAL INFECTION; ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENCY; FEMALE; HUMAN; IN VITRO STUDY; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MIC90; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; INTRAABDOMINAL INFECTIONS; PATHOGENICITY; PSEUDOMONAS AERUGINOSA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; METRONIDAZOLE; MIDDLE AGED; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA;

EID: 84976892814     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03074-15     Document Type: Article

References (20)

1. Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, Malangoni M, Velmahos G, Coimbra R, Koike K, Leppaniemi A, Biffl W, Balogh Z, Bendinelli C, Gupta S, Kluger Y, Agresta F, Di Saverio S, Tugnoli G, Jovine E, Ordonez CA, Whelan JF, Fraga GP, Gomes CA, Pereira GA, Yuan KC, Bala M, Peev MP, Ben-Ishay O, Cui Y, Marwah S, Zachariah S, Wani I, Rangarajan M, Sakakushev B, Kong V, Ahmed A, Abbas A, Gonsaga RA, Guercioni G, Vettoretto N, Poiasina E, Diaz-Nieto R, Massalou D, Skrovina M, Gerych I, Augustin G, Kenig J, Khokha V, Trana C, Kok KY, Mefire AC, Lee JG, Hong SK, Lohse HA, Ghnnam W, Verni A, Lohsiriwat V, Siribumrungwong B, El Zalabany T, Tavares A, Baiocchi G, Das K, Jarry J, Zida M, Sato N, Murata K, Shoko T, Irahara T, Hamedelneel AO, Naidoo N, Adesunkanmi AR, Kobe Y, Ishii W, Oka K, Izawa Y, Hamid H, Khan I, Attri A, Sharma R, Sanjuan J, Badiel M, Barnabe R. 2014. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW study. World J Emerg Surg 9:37. http://dx.doi.org/10.1186/1749-7922-9-37.
2. Center for Disease Dynamics Economics & Policy. 2013. ResistanceMap database: The Surveillance Network. USA Center for Disease Dynamics, Economics & Policy, Washington, DC. http://www.cddep.org/map. Accessed 17 March 2016.
3. European Centre for Disease Prevention and Control. 2013. Antimicrobial resistance surveillance in Europe 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf. Accessed 17 March 2016.
4. Merck & Co., Inc. 2015. Zerbaxa prescribing information. Merck & Co., Inc., Whitehouse Station, NJ.
5. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55:2390-2394. http://dx.doi.org/10.1128/AAC.01737-10.
6. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70:137-141. http://dx.doi.org/10.1016/j.diagmicrobio.2011.02.004.
7. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagace-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, III, Karlowsky JA. 2014. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 74:31-51. http://dx.doi.org/10.1007/s40265-013-0168-2.
8. Farrell DJ, Sader HS, Flamm RK, Jones RN. 2014. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 43:533-539. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.032.
9. Solomkin JS, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. 2015. Ceftolozane/tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60:1462-1471. http://dx.doi.org/10.1093/cid/civ097.
10. Clinical and Laboratories Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. CLSI document M100-S26. Clinical and Laboratories Standards Institute, Wayne, PA.
11. Blot S, De Waele JJ, Vogelaers D. 2012. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 72:e17-e32. http://dx.doi.org/10.2165/11599800-000000000-00000.
12. Augustin P, Dinh AT, Valin N, Desmard M, Crevecoeur MA, Muller-Serieys C, Woerther PL, Marmuse JP, Bronchard R, Montravers P. 2013. Pseudomonas aeruginosa post-operative peritonitis: clinical features, risk factors, and prognosis. Surg Infect (Larchmt) 14:297-303. http://dx.doi.org/10.1089/sur.2012.084.
13. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, Dupont H. 2009. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 63:785-794. http://dx.doi.org/10.1093/jac/dkp005.
14. Heizmann WR, Dupont H, Montravers P, Guirao X, Eckmann C, Bassetti M, Garcia MS, Capparella MR, Simoneau D, Bodmann KF. 2013. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. J Antimicrob Chemother 68(Suppl 2):ii45-ii55. http://dx.doi.org/10.1093/jac/dkt144.
15. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak R, Ellis-Grosse EJ, Loh E, 301 Study Group. 2005. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [study ID numbers: 3074A1-301-WW; ClinicalTrials.gov identifier: NCT00081744]. BMC Infect Dis 5:88. http://dx.doi.org/10.1186/1471-2334-5-88.
16. Qvist N, Warren B, Leister-Tebbe H, Zito ET, Pedersen R, McGovern PC, Babinchak T. 2012. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect (Larchmt) 13:102-109. http://dx.doi.org/10.1089/sur.2011.048.
17. Castanheira M, Mills JC, Farrell DJ, Jones RN. 2014. Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother 58:6844-6850. http://dx.doi.org/10.1128/AAC.03681-14.
18. Livermore DM, Mushtaq S, Ge Y. 2010. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65:1972-1974. http://dx.doi.org/10.1093/jac/dkq248.
19. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 57:6305-6310. http://dx.doi.org/10.1128/AAC.01802-13.
20. Walkty A, Karlowsky JA, Adam H, Baxter M, Lagace-Wiens P, Hoban DJ, Zhanel GG. 2013. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 57:5707-5709. http://dx.doi.org/10.1128/AAC.01404-13.